Answers are grounded in this paper and cite their sources.
Randomized trial evaluates intravenous magnesium sulfate's effectiveness for acute asthma in children, suggesting improved outcomes.
BACKGROUND: Asthma is the most common pediatric chronic disease and currently affects 7.1 million children in the United States. Many children experience acute asthma exacerbations. Many children also require hospitalization despite treatment in an emergency department with current standard therapy (corticosteroids, albuterol, and ipratropium). These hospitalizations may be avoided if effective adjunctive therapies can be developed to adequately treat severe exacerbations. METHODS: Publications were searched in the PubMed database using the following keywords: magnesium AND asthma AND children AND randomized controlled trial. A total of 30 publications were returned. References of relevant articles were also screened. We included publications of controlled randomized trials where intravenous magnesium sulfate was studied in children (age < 18 years) with acute asthma (n = 7). We excluded studies in adults or trials with other formulations of magnesium (e.g., nebulized). RESULTS: for the treatment of pediatric acute asthma. CONCLUSIONS: in pediatric acute asthma. Pediatr Pulmonol. 2016;51:1414-1421.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: